Survivin, a member of the inhibitory apoptosis protein family, gives rise, by an alternative splicing, to four variants with different functions. Many experimental studies indicate that p53 can regulate the expression of survivin and some of its splice variants. Although both the expression of survivin splice variants and the p53 gene were frequently altered in human cancers, nothing is known about their interactions in in vivo tumour samples. Here, we report that, in 162 breast carcinomas, p53 mutations are significantly associated with an increased expression of survivin and, in particular, its antiapoptotic splice variants (survivin-DEx3 and survivin-3B). The upregulation of these variant expressions is particularly related to p53 mutations occurring in the residues belonging to the tetramerization domain. The loss of heterozygosity in the p53 gene is also associated with an increased expression of the survivin-DEx3 variant. The expression of the proapoptotic variants (survivin-2B and survivin-2a) is not affected by any of these alterations. Our results provide for the first time in vivo evidence that, in human breast cancer, the survivin expression as well as its splicing depends on the p53 status. The results also suggest that the upregulation of antiapoptotic survivin variant expression by the mutant p53 may increase breast cancer cells survival and resistance to therapy.
Survivin is the smallest member of the inhibitory apoptosis protein (IAP) families that are characterized by their BIR domain (baculovirus IAP repeat) allowing caspase inhibition (Altieri, 2003) . The antiapoptotic function of survivin seems to occur by binding specific caspase-3, -7 and -9, but this fact remains not clearly defined. Survivin overexpression was observed in common human cancers (as lung, colon, pancreas, prostate and breast), and was associated with tumour progression and chemoresistance. Survivin (Birc5) gene is localized at 17q25 and consists of four exons and three introns resulting in the main expressed transcript, survivin (Ambrosini et al., 1997 (Ambrosini et al., , 1998 . Survivin-2B results from the introduction of a new exon of 69 bp and survivinDEx3 from the exclusion of exon 3, leading to a frame shift and the loss of 102 bp. Despite these modifications, survivin-DEx3 preserves the antiapoptotic function, whereas survivin-2B seems to have a proapoptotic activity (Mahotka et al., 1999) . Survivin-3B results from the inclusion of a part of intron 3 and it is 165 bp longer than survivin, but gives rise to a 120-amino-acid protein because of a stop codon in the new exon 3B. This variant preserves a complete BIR domain and is supposed to act as an antiapoptotic protein (Badran et al., 2004) . Survivin-2a is the smallest survivin transcript resulting from the inclusion of a part of a 3 0 -197 bp region of intron 2. It encodes a truncated protein of 74 amino acids resulting in a truncated BIR domain and may have a proapoptotic activity (Caldas et al., 2005) .
The mechanisms underlying tumour-associated survivin re-expression are still unclear because of the high complexity of its regulation. Although many pathways were reported to be implied in the regulation of survivin expression (Tran et al., 2002; Altieri, 2003; Sommer et al., 2003) , several studies have demonstrated loss of wild-type (wt)-p53-dependent re-expression of survivin. It was found that wt-p53 can transcriptionally repress survivin expression by interfering with E2F-1 after an interaction with survivin core promoter harbouring a potential p53-binding site (Hoffman et al., 2002) . It was also observed that the recruitment of Sin-3 (a corepressor factor) and histone deacetylases (HDAC) by p53 is involved in the inhibitory effect of p53 on survivin (Murphy et al., 1999; Hoffman et al., 2002) . However, other studies did not find that p53 could physically associate the p53-binding site with the survivin core promoter, but reached the similar conclusion that HDAC was involved in the repressing effects of p53 on survivin expression (Mirza et al., 2002; Punga and Akusjarvi, 2003; Este`ve et al., 2005) . The repressive effect of p53 on the survivin promoter may also be indirect and may depend on the p53-activating synthesis of a repressor protein, as through the P53/P21/Rb/E2F pathway (Hoffman et al., 2002; Lohr et al., 2003) . Survivin is also expressed in a cell-cycle-regulated manner in the G2/S phase of proliferating cells, and is rapidly downregulated by cell-cycle arrest in the G1 phase. When expressed at mitosis, survivin localizes to various components of the mitotic apparatus, such as centrosomes, microtubules of the metaphase spindle and midbodies (Altieri, 2003) .
p53 is a nuclear protein that is essential for cell-cycle control, DNA repair and induction of apoptosis by many stresses. The gene is located on 17p13.1 and encodes a 393-amino-acid protein T divided into three principal domains. The N-terminal domain includes the transactivation region and the second is the central core highly conserved DNA-binding domain. This domain contains a sandwich of two antiparallel b-sheets and two large loops (L2 and L3) that are held together in part by a tetrahedrally coordinated zinc atom. The third one is the C-terminal domain that includes the tetramerization domain (Bullok and Fersht, 2001) .
The p53 gene is mutated in half of human cancers and in 20-25% of breast cancer cases. It is now well established that p53-null mutations (frameshift, nonsense and splicing junction mutations) completely destroy the functionality of the protein (Zhou et al., 1999) . In addition, missense mutations that occur within the L2 and L3 loops (residues 163-195 and 236-251) disrupt its stability (Cho et al., 1994) . Certain categories of missense mutations also occurring in the core domain can be distinguished by either they affected residues disturbing the structure/stabilization of the protein (R175, C242 and D281) or its DNA contact ability (K120, R248 and R273) (Bullok and Fersht, 2001 ). Moreover, some mutant p53 (such as R175H, R248W or R273H) acquires a gain of function and contributes to tumour malignancy and chemoresistance (van Oijen and Slootweg, 2000; Xu and el-Gewely, 2003) . Furthermore, one common polymorphism of p53 at codon 72 (exon 4), resulting in either an arginine (Arg72) or proline (Pro72), was shown to differ in its functional activity. Indeed, this polymorphism occurs in the proline-rich region of p53, which is necessary for the protein to fully induce apoptosis, and it was demonstrated that the Arg72 variant induces apoptosis more efficiently than the Pro72 variant (Dumont et al., 2003) .
In breast cancer, p53 mutations as well as loss of heterozygosity (LOH) at 17p13 were shown to be associated with an increased survivin expression (Tsuji et al., 2004) . However, only the main transcript of survivin was analysed in this study and LOH was determined in a region distal to the p53 gene. Because both overexpression of survivin and p53 alterations were frequently detected in breast cancer, we explored the relationship between p53 status (mutations, LOH and codon 72 polymorphism) and expression levels of survivin and its splice variants. Our results show that the antiapoptotic survivin expression is specifically associated with p53 alterations.
Expression of survivin transcripts: Semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) results show that survivin mRNA was the most dominant transcript, whereas expression of the variants appears at weak levels ( Figure 1a ). Western blot analysis was restrained to survivin, survivin-DEx3 and survivin-2B, because only their antibodies are currently available to discriminate these different transcripts on the protein levels. The results show the predominant presence of survivin comparatively to the two variants (survivin-DEx3 and survivin-2B). Comparison with quantitative RT-PCR showed an identical protein and mRNA ratio expression levels between survivin-2B and survivin as well as between survivinDEx3 and survivin ( Figure 1b) . Therefore, the expression of each transcript was determined in breast carcinomas by quantitative RT-PCR using specific primers and probes ( Figure 2 ). The apparied Wilcoxon's test revealed that the differences of expression between each variant and the main transcript survivin were statistically significant (Po0.0001 for survivin-DEx3, -3B and -2B and Po0.0003 for survivin-2a). The differences among the variants were also statistically significant. Survivin-2a is the predominant variant (P ¼ 0.0033 vs survivin-DEx3, Po0.0001 vs survivin-3B and -2B) followed by survivin-DEx3 (Po0.0001 vs survivin-3B and -2B) and survivin-2B (Po0.0001 vs survivin-3B). The survivin-3B variant was the less expressed ( Figure 1c ). The correlation Z-test demonstrated that survivin-DEx3, survivin-3B and survivin-2B expressions were correlated with survivin. In contrast, survivin-2a expression did not correlate with survivin one (Figure 1d ).
p53 gene mutation analyses: p53 mutational status was explored at exons 2-10 in the 162 breast carcinomas. The results show the presence of 32 mutations, including four found twice in different carcinomas (Table 1) . Identical frequencies of 47% (15/32) for null (frameshift and nonsense) and missense mutations were observed in the mutated population. These mutations affect normal protein functions and some of them (R175H and R248W) were characterized to acquire novel oncogenic gain of function (van Oijen and Slootweg, 2000) .
LOH and p53 gene codon 72 polymorphism analyses: We used two microsatellite markers to characterize LOH in the 17p13.1 region: p53CA located 25 kb upstream from p53 and p53 penta located in intron 1 of the gene (Cawkwell et al., 1994) . The results showed that 82/162 cases were informative for both markers, but only 11 (13%) have LOH simultaneously in the two regions. In the whole population, p53CA was more informative (91%, 147/162) than p53 penta (23%, 91/162). However, p53 penta was more affected by LOH (23.08%) than p53CA (20.41%) in the analysed carcinomas. Among the 32 mutated carcinomas, nine have also LOH in the p53 gene. The codon 72 polymorphism was analysed in 161 carcinomas. The Arg/Arg polymorphism was detected in 99 samples (61%), followed by Arg/Pro in 51 (32%) and Pro/Pro in 11 (7%) samples.
Correlation of p53 gene alterations with survivin transcript expressions: When general alterations of p53 included LOH at the both loci (p53CA and p53 penta) and mutations were considered, expression of survivin (P ¼ 0.0482) and survivin-DEx3 (P ¼ 0.0027) was significantly increased in carcinomas with these alterations.
p53 alterations and antiapoptotic survivin variants F Végran et al A trend for survivin-3B (P ¼ 0.0605) was however observed. The comparisons with LOH status indicate that LOH at p53CA did not influence survivin transcript expression. In contrast, LOH at p53 penta was associated with increased survivin-DEx3 expression. In parallel, there was no correlation between any of the codon 72 polymorphism and survivin transcript expression (Table 2) .
We then compared the expression of each survivin transcript with real p53 gene alterations (intragenic LOH at p53 penta and mutations) (Figure 3 ). There were significant relations between the increased expression of survivin, survivin-DEx3 and survivin-3B and p53 alterations (Figure 3a) . The expression of survivin-2B and survivin-2a was not different between normal and altered p53 (P ¼ 0.1212 and 0.1227, respectively). To determine the role of p53 mutants on the alternative splice variants of survivin, we compared the expression of each survivin transcript according to the absence or presence of p53 mutations. Whereas survivin, survivinDEx3 and survivin-3B were significantly more expressed in samples with p53 mutations, the expression of p53 alterations and antiapoptotic survivin variants F Végran et al survivin-2B and survivin-2a was not different between wt-and mutated p53 (P ¼ 0.2249 and 0.1082, respectively) (Figure 3b ). These results indicate that the effect of p53 alterations on antiapoptotic survivin transcript was mainly owing to mutations and that intragenic LOH affect partially their expression. Therefore, we asked whether a specific domain of p53 may be more related to this upregulation. Domain 2 was the more affected by p53 mutations (72%, 23/32), comparatively to domains 1 (13%, 4/32) and 3 (16%, 5/32) ( Table 1) . When mutated tumours in each domain were compared with wt-p53 tumours and mutations outside the considered domain, a significant association was found between the expression of survivin-DEx3 with both second and third domain mutations, as well as with survivin-3B and third domain mutations (Figure 3c ). No relation was found for the remaining two variants expression (survivin-2B and survivin-2a).
In this study, we firstly characterize each survivin transcript expression in 162 breast carcinomas. Until now, all the expressions of survivin splice variants have not been studied yet in breast cancer (Nasu et al., 2002; O'Driscoll et al., 2003; Ryan et al., 2005) . The results show that, except for survivin-2a variant, expression of survivin correlated positively with the three splice variants survivin-2B, survivin-DEx3 and survivin-3B. These positive correlations were in agreement with those observed in breast carcinomas (Ryan et al., 2005) . In our study, survivin-2a is expressed in all samples, such as Figure 2 Nucleotide sequences of primers and probes used in this study. The sets of primers for survivin transcripts allow the synthesis of fragments of 152, 108, 193, 198 and 81 bp for survivin, survivin-DEx3, survivin-3B, survivin-2B and survivin-2a, respectively. A pool of four normal mammary tissues obtained from Clontech (Mountain View, CA, USA). MW indicates molecular weight. PCR amplification for survivin, survivin-2B, survivin-DEx3 and survivin-3B was performed as described previously (Ve´gran et al., 2005) . For amplification of survivin-2a, we used the same set of primers (at 600 nM) as for the real-time quantitative PCR, which results in a 60-bp fragment. (b) Western blot assay for survivin, survivin-DEx3 and survivin-2B. MCF-7 and HBL100 cell line were used as positives controls. b-Actin was used as an internal control. The protein (WB) and mRNA (q-PCR: quantitative RT-PCR) ratio expression levels between survivin-2B or survivin-DEx3 and survivin are shown beneath the blots. For Western blot, membranes were probed with specific polyclonal antibodies (b-actin, survivin, survivin-DEx3, survivin-2B; Abcam, Cambridge, England), diluted at 1:5000, for 1 h at room temperature. After washing, the membrane was incubated with biotinylated anti-rabbit immunoglobulin (Ig)G (1:10 000) secondary antibody overnight at 41C and streptavidin-horseradish peroxidase (HRP) (1:5000) for 1 h at room temperature. Signals were detected using a chemiluminescent detection system (ECL Advance Western Blotting Detection Kit; Amersham, Buckinghamshire, England). The quantitative PCR was performed on ABI PRISM 7300 (Applied Biosystems, Foster City, CA, USA) by using the Taqman method. An analysis of 18S gene was used to assess cDNA quality and as a reference control gene. Primers and probes for survivin transcripts are located as described in Figure 2 . Amplification was performed in a total volume of 25 ml in the presence of 12.5 ml Universal Master Mix (Applied Biosystems), 80 nM of each primer and 50 nM probe for 18S gene, 300 nM primers and 150 nM probe for survivin transcripts, and 12.5 ng cDNA (or water as a negative control). PCR programme was constituted of a 10 min initial denaturation step at 951C, followed by 40 cycles of 15 s at 951C and 1 min at 601C. All samples were amplified in duplicate and results were analysed by the 2 ÀDC t method (Livak and Schmittgen, 2001) . ( p53 alterations and antiapoptotic survivin variants F Végran et al survivin, and its expression was higher in comparison with the other three splice variants. The underlying biological hypothesis is that survivin-2B and survivin-2a splice variants might function in effect as dominant negatives so that their expression might concurrent with survivin. That is why survivin-2B did correlate with 
Abbreviations: LOH, loss of heterozygosity; PCR, polymerase chain reaction. a P-values were obtained with Mann-Whitney U-test for LOH, and with Kruskal-Wallis test for codon 72 polymorphism comparison. LOH was determined on specific PCR products of tumours and corresponding normal cells (lymphocytes). PCR was performed with synthesized labelled primers specific to the microsatellite p53CA localized out of p53 gene as well as to the microsatellite p53 penta localized in intron 1 of the p53 gene (Genome Database). LOH analysis was carried out using ABI PRISM 310 as described previously (Franco et al., 2003) . Sequence analysis of codon 72 polymorphism in exon 4 was performed by direct sequencing. Abbreviations: I, intron; E, exon; X, stop; SH3, Src homology-3; L, loop; S, sheet; H, helix. a From IARC: http://www-p53.iarc.fr. b Mutations detected in two different carcinomas. A series of 162 patients with primary breast carcinomas was studied. DNA was extracted from frozen tissue samples using the phenol-chloroform method. Mutations in the p53 gene were analysed by direct sequencing on an ABI PRISM 310 (Applied Biosystems) as described previously (Franco et al., 2003) .
p53 alterations and antiapoptotic survivin variants F Végran et al survivin expression? This might be explained by a different potential in its apoptotic effect. Indeed, experimental studies have shown that survivin-2B reduced cell survival frequencies comparatively to survivin (Mahotka et al., 1999) , but survivin-2a seems to strongly attenuate the antiapoptotic activity of survivin even in the absence of an apoptotic stimulus (Caldas et al., 2005) . Survivin expression regulation is still unknown, but many studies indicate that p53 might have a major role in this regulation (Hoffman et al., 2002; Mirza et al., 2002; Lohr et al., 2003; Punga and Akusjarvi, 2003; Zhu et al., 2004) . It was also shown that p53 has also an effect on different gene expression at the mRNA splicing levels (Maxwell et al., 1999; Moyret-Lalle et al., 2001; Xu and el-Gewely, 2003) , including splicing of survivin (Zhu et al., 2004) .
Thus, we characterized p53 status in the same population of breast carcinomas and found that p53 mutations were significantly associated with an increased expression of survivin and its antiapoptotic splice variants. Our results are consistent with Zhu et al. (2004) study, reporting in leukaemia cell lines that antiapoptotic survivin and survivin-DEx3 are downregulated by wt-p53, whereas proapoptotic survivin-2B is upregulated. However, no correlation was found for survivin-2B and survivin-2a with p53 gene status in our study. The fact that survivin-2B and survivin-2a were not associated with p53 alterations suggests that mutant's p53 might affect specifically antiapoptotic survivin variants in breast carcinomas.
Wt-p53 can trigger cell growth arrest and apoptosis in response to genomic damage by either trans-activating proapoptotic genes or trans-repressing antiapoptotic genes, and all functions of p53 depend on sequencespecific DNA contact ability and the wt-conformation of the protein. Although the b-sandwich is not directly involved in DNA binding, mutations affecting its structure influence the structure/stabilization of the protein. Destabilization of the protein structure is also expected for mutations localized in the tetramerization domain (Bullok and Fersht, 2001 ). In our study, all the mutations detected have a critical effect on the protein functions.
The mechanism whereby p53 plays a part in the splicing process is still largely unknown. However, our results indicate that the association between antiapoptotic survivin variant (survivin, survivin-DEx3 and survivin-3B) expression and p53 alterations seems independent of the apoptotic potential of the codon 72 polymorphism, as it did not influence the expression of survivin and its splice variants. These observations agree with the fact that p53-mediated negative regulation of transcription could occur independently of apoptosis (Dumont et al., 2003; Lohr et al., 2003) . In contrast, the haploinsufficiency of p53 seems to affect survivin splice variants, as LOH in the p53 gene was significantly associated with the increased expression of the survivinDEx3 variant. These data agree with the fact that a p53 gene dosage may be necessary for p53 function (Yoon et al., 2002) , and may explain the absence of association with the microsatellite p53CA, located 25 kb upstream from the gene. The majority of p53 mutations associated with tumours affects the amino acids (at exons 5-8) in the central regions of p53, but the exons 4 and 10 are also mutated (Soussi and Beroud, 2001) . Consistently, our results show that the majority of mutations were clustered in this direct DNA-binding domain. Curiously, mutations of the third domain are associated with both survivin-3B and survivin-DEx3 increased expression, beside its low-frequency mutation. This tetramerization domain is required for the p53 structure and it has been shown that tetramerization-defective mutant R342X impaired sequence-specific DNA binding and failed to trans-activate P21, Bax or IGF-BP3 (Zhou et al., 1999) .
However, several studies indicate that certain types of p53 point mutations, a so-called gain of function mutants, exert activities that the wt-p53 does not. These studies show that some p53 mutants not only lose their tumour suppressor function but also gain oncogenic functions (van Oijen and Slootweg, 2000; Xu and elGewely, 2003) . Interestingly, some specific mutant (such as G245C) has the ability to induce alternative splicing (Xu and el-Gewely, 2003) . Thus, the presence of mutant p53 may strongly affect the expression of survivin splicing either by a loss of normal functions to transrepress the expression of antiapoptotic survivin variants or by a gain of function resulting in trans-activation of these variants expression. It could be of great interest to determine the role of specific mutant p53 in survivin splicing processes.
In conclusion, the present study indicates that the expression of survivin antiapoptotic variants is upregulated in breast carcinomas with altered p53. Together with deregulation of survivin splicing, favouring the expression of antiapoptotic variants may render breast carcinoma cells more resistant to chemotherapy. Abrogation of mutant p53 proteins can thus increase apoptotic survivin variant expression, reduce cell survival and sensitize tumour cells to treatment.
